ArticleBMC pulmonary medicine2026
Long-term prognostic impact of clinical frailty scale on acute exacerbation of fibrotic interstitial lung disease: a retrospective cohort study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute exacerbations (AE) of fibrotic interstitial lung disease (fILD) are associated with a poor prognosis; however, the factors that predict long-term outcomes remain unclear. This study aimed to evaluate whether pre-admission frailty, as assessed using the Clinical Frailty Scale (CFS), predicts 1-year mortality and other relevant outcomes in patients with AE-fILD.
methodsThis single-centre retrospective study included 125 patients hospitalised for AE-fILD between January 2017 and September 2023. Patients were categorised into low (score: 1-4) and high (score: 5-9) CFS groups based on their CFS scores. The primary outcome was 1-year mortality, and the secondary outcomes included in-hospital mortality, 90-day mortality, and home discharge. Prognostic associations were evaluated using Kaplan-Meier and multivariable Cox regression analyses, adjusted for age, lactate dehydrogenase levels, SpO₂/F
resultsThe median patient age was 78 years, and 41.6% of patients were included in the high CFS group. Kaplan-Meier analysis revealed a significantly lower 1-year survival in the high-CFS group (log-rank, p < 0.001). After adjustment, a high CFS score remained independently associated with increased 1-year mortality (adjusted hazard ratio, 2.20; 95% confidence interval, 1.31-3.68; p = 0.003). Higher in-hospital and 90-day mortality rates and lower home discharge rates were observed in the frail subgroup.
conclusionPreadmission frailty, as assessed using the CFS, independently predicts 1-year mortality and is associated with adverse outcomes in patients with AE-fILD. Incorporating a CFS-based frailty assessment may provide a simple and useful prognostic tool to inform clinical decision-making and promote patient-centred care.
trial registrationAn independent ethics committee approved the study (Institutional Review Board of the Kobe City Medical Center General Hospital [number zn241009 date October 8, 2024]), which was performed in accordance with the Declaration of Helsinki and Guidelines for Good Clinical Practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.